Next Article in Journal
Unmasking of Gitelman Syndrome during Pregnancy in an Adolescent with Thyrotoxic Crisis
Previous Article in Journal
Trends in Childhood Poison Exposures and Fatalities: A Retrospective Secondary Data Analysis of the 2009–2019 U.S. National Poison Data System Annual Reports
Case Report

Ivabradine–Flecainide as Breakthrough Drug Combination for Congenital Junctional Ectopic Tachycardia: A Case Report and Literature Review

1
Division of Cardiology, Department of Pediatrics, Santobono- Pausilipon Children Medical Hospital, 80129 Naples, Italy
2
Department of Woman, Child and General and Specialist Surgery, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
3
Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, Pediatrics Section, University of Salerno, 84081 Baronissi, Italy
4
Department of Translational Medical Science, Pediatrics Section, University of Naples “Federico II”, 80126 Naples, Italy
5
Pediatric Emergency and Short Stay Unit, Santobono-Pausilipon Children’s Hospital, 80129 Naples, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Maurizio Aricò
Pediatr. Rep. 2021, 13(4), 624-631; https://doi.org/10.3390/pediatric13040074
Received: 16 September 2021 / Revised: 4 November 2021 / Accepted: 19 November 2021 / Published: 23 November 2021
Congenital junctional ectopic tachycardia (CJET) is a rare tachyarrhythmia that remains difficult to manage, with suboptimal control in most cases. Here, we report literature research on the use of ivabradine in the treatment of pediatric junctional ectopic tachycardia (JET), both congenital and postoperative, and describe the successful use of ivabradine–flecainide association for CJET therapy resistant to other antiarrhythmic agents. This new drug combination was effective in completely suppressing JET. Ivabradine–flecainide combination may be considered a new therapeutic strategy of CJET with a satisfactory efficacy/tolerability ratio in patients resistant to conventional drug combinations. View Full-Text
Keywords: ivabradine; tachycardia; junctional; pediatrics; congenital ivabradine; tachycardia; junctional; pediatrics; congenital
Show Figures

Figure 1

MDPI and ACS Style

Di Marco, G.M.; De Nigris, A.; Pepe, A.; Pagano, A.; Di Nardo, G.; Tipo, V. Ivabradine–Flecainide as Breakthrough Drug Combination for Congenital Junctional Ectopic Tachycardia: A Case Report and Literature Review. Pediatr. Rep. 2021, 13, 624-631. https://doi.org/10.3390/pediatric13040074

AMA Style

Di Marco GM, De Nigris A, Pepe A, Pagano A, Di Nardo G, Tipo V. Ivabradine–Flecainide as Breakthrough Drug Combination for Congenital Junctional Ectopic Tachycardia: A Case Report and Literature Review. Pediatric Reports. 2021; 13(4):624-631. https://doi.org/10.3390/pediatric13040074

Chicago/Turabian Style

Di Marco, Giovanni M., Angelica De Nigris, Angela Pepe, Annamaria Pagano, Giangiacomo Di Nardo, and Vincenzo Tipo. 2021. "Ivabradine–Flecainide as Breakthrough Drug Combination for Congenital Junctional Ectopic Tachycardia: A Case Report and Literature Review" Pediatric Reports 13, no. 4: 624-631. https://doi.org/10.3390/pediatric13040074

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop